LEADER 02391nam 2200529 450 001 9910812383303321 005 20230803030624.0 010 $a1-78084-162-0 035 $a(CKB)2670000000391287 035 $a(EBL)1179620 035 $a(OCoLC)851970656 035 $a(SSID)ssj0001599917 035 $a(PQKBManifestationID)16306388 035 $a(PQKBTitleCode)TC0001599917 035 $a(PQKBWorkID)14892429 035 $a(PQKB)11462420 035 $a(MiAaPQ)EBC1179620 035 $a(Au-PeEL)EBL1179620 035 $a(EXLCZ)992670000000391287 100 $a20220517d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aAdvances in pulmonary neuroendocrine tumor management /$feditor, Kjell O?berg 205 $a1st ed. 210 1$aLondon, England :$cFuture Medicine Ltd.,$d[2013] 210 4$dİ2013 215 $a1 online resource (101 p.) 300 $aDescription based upon print version of record. 311 $a1-78084-164-7 327 $aTitle page; Copyright page; Contents; Foreword. Advances in pulmonary neuroendocrine tumor management; 1. Classification; 2. Molecular imaging & peptide receptor radionuclide therapy; 3. Biotherapy: somatostatin analogs and IFN-?; 4. Typical and atypical bronchial carcinoid tumors; 5. Small-cell lung cancer and large-cell neuroendocrine tumors of the lung; 6. Thymic neuroendocrine tumors; 7. Algorithm for management of bronchopulmonary neuroendocrine tumors; Index 330 $aPulmonary neuroendocrine tumors (NETs) account for approximately one-quarter of all malignant lung cancers, the vast majority being represented by small-cell lung carcinoma. This thorough overview of this challenging field from international experts explores the various existing and emerging treatment options across the NET spectrum together with approaches to diagnosis and monitoring of disease. 606 $aNeuroendocrine tumors$xTreatment 606 $aLungs$xTumors$xTreatment 615 0$aNeuroendocrine tumors$xTreatment. 615 0$aLungs$xTumors$xTreatment. 676 $a616.99424 702 $aO?berg$b Kjell 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910812383303321 996 $aAdvances in pulmonary neuroendocrine tumor management$94038750 997 $aUNINA